2-Carboxy-chinoxalin-1-N-oxid | 18950-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-Carboxy-chinoxalin-1-N-oxid
• 英文别名: 1-oxy-quinoxaline-2-carboxylic acid；1-Oxy-chinoxalin-2-carbonsaeure；2-Carboxyquinoxaline 1-oxide；1-oxidoquinoxalin-1-ium-2-carboxylic acid
• CAS: 18950-49-7
• 化学式: C₉H₆N₂O₃
• 分子量: 190.158
• InChiKey: XUPCBLUMRUUBPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-喹喔啉羧酸1,4-二氧化物 在 sodium hydroxide 、 sodium dithionite 作用下， 生成 2-Carboxy-chinoxalin-1-N-oxid
  参考文献：
  名称：

  Elina; Magidson, Zhurnal Obshchei Khimii, 1955, vol. 25, p. 161,163; engl. Ausg. S. 145, 147

  摘要：

  DOI：

文献信息

• Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
  申请人：Pfizer Inc

  公开号：US20040097554A1

  公开（公告）日：2004-05-20

  The present invention relates to compounds of the formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , and L are as described in the specification. The present invention also relates to pharmaceutical compositions that include compounds of the formula (I) and a pharmaceutically acceptable carrier. Moreover, the present invention relates to methods of using the above-described compounds and compositions to treat and prevent diseases and conditions including those that may be treated or prevented by antagonizing the CCR1 receptor.

  本发明涉及式(I)的化合物1，其中R1、R2、R3、R4、R5、R7和L如规范中所述。本发明还涉及包括式(I)的化合物和药学上可接受的载体的制药组合物。此外，本发明涉及使用上述化合物和组合物治疗和预防疾病和病症的方法，包括那些通过拮抗CCR1受体可以治疗或预防的疾病和病症。
• HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS
  申请人：Pfizer Products Inc.

  公开号：EP1558587A1

  公开（公告）日：2005-08-03
• [EN] HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES AS IMMUNOMODULATORY AGENTS<br/>[FR] DERIVES AMIDE D'ACIDE HEXANOIQUE HETEROARYLE UTILES EN TANT QU'AGENTS IMMUNOMODULATEURS
  申请人：PFIZER PROD INC

  公开号：WO2004039787A1

  公开（公告）日：2004-05-13

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, R7, and L are as described in the specification. The present invention also relates to pharmaceutical compositions that include compounds of the formula (I) and a pharmaceutically acceptable carrier. Moreover, the present invention relates to methods of using the above-described compounds and compositions to treat and prevent diseases and conditions including those that may be treated or prevented by antagonizing the CCR1 receptor.
• Elina; Magidson, Zhurnal Obshchei Khimii, 1955, vol. 25, p. 161,163; engl. Ausg. S. 145, 147
  作者：Elina、Magidson

  DOI：——

  日期：——